Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cognition Therapeutics Inc
(NQ:
CGTX
)
1.880
+0.040 (+2.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cognition Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
July 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 22, 2024
Via
Benzinga
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
May 21, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
A Preview Of Cognition Therapeutics's Earnings
March 25, 2024
Via
Benzinga
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024
May 07, 2024
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
May 07, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
April 29, 2024
- Top-line Results Expected in the Second Half of 2024 -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
April 22, 2024
Via
Benzinga
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
April 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
April 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
April 01, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023
March 26, 2024
CGTX stock results show that Cognition Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
March 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering
March 15, 2024
Via
Investor Brand Network
Earnings Scheduled For March 26, 2024
March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
Via
Benzinga
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
March 15, 2024
Conference Call and Live Audio Webcast Scheduled for March 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
March 15, 2024
The Dow Jones index closed lower by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
March 14, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
March 11, 2024
Via
Benzinga
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
March 11, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
March 06, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
February 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
February 06, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 04, 2024
Via
Benzinga
Cognition Therapeutics CEO Issues Letter to Shareholders
January 04, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
December 11, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 04, 2023
Via
Benzinga
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
November 16, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
November 15, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.